Second Generation of Bace-1 Inhibitors. Part 1: The Need for Improved Pharmacokinetics.
Charrier, N., Clarke, B., Cutler, L., Demont, E., Dingwall, C., Dunsdon, R., Hawkins, J., Howes, C., Hubbard, J., Hussain, I., Maile, G., Matico, R., Mosley, J., Naylor, A., O'Brien, A., Redshaw, S., Rowland, P., Soleil, V., Smith, K.J., Sweitzer, S., Theobald, P., Vesey, D., Walter, D.S., Wayne, G.(2009) Bioorg.Med.Chem.Lett. 19: 3664
- PubMed: 19428244 
- DOI: 10.1016/j.bmcl.2009.03.165
- Primary Citation of Related Structures:  
- PubMed Abstract: 
Inhibition of the aspartyl protease BACE-1 has the potential to deliver a disease-modifying therapy for Alzheimer's disease. We have recently disclosed a series of transition-state mimetic BACE-1 inhibitors showing nanomolar potency in cell-based ass ...